| US 7,468,359 B2 | ||
| Compositions comprising oxophosphonate-based metalloproteinase inhibitors | ||
| Eli Breuer, Jerusalem (Israel); Reuven Reich, Rehovot (Israel); and Claudio Salomon, Rosaro (Argentina) | ||
| Assigned to Yissum Research Develpment Company of the Hebrew University of Jerusalem, Jerusalem, Ill. (US) | ||
| Filed on May 23, 2006, as Appl. No. 11/419,893. | ||
| Application 11/419893 is a division of application No. 10/110317, granted, now 7,101,864, previously published as PCT/IL00/00579, filed on Sep. 19, 2000. | ||
| Claims priority of application No. 132315 (IL), filed on Oct. 11, 1999. | ||
| Prior Publication US 2006/0199787 A1, Sep. 07, 2006 | ||
| Int. Cl. A61K 31/675 (2006.01); C07F 9/6533 (2006.01); C07F 9/547 (2006.01) | ||
| U.S. Cl. 514—89 [514/90; 514/91; 544/157; 546/22; 248/413] | 8 Claims |
| 1. A compound selected from the group consisting of:
N-(2-[4-morpholino]ethyl)phosphonoformamide,
N-(2-[1-piperidino]ethyl)phosphonoformamide, and
N-(2-[1-pyrrolidino]ethyl)-phosphonoformamide.
|